A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma
Timothy Brighton(Prince of Wales Hospital), Hartmut Goldschmidt(Heidelberg University), Sepideh Nemat(Janssen (United Kingdom)), Hila Magen(Sheba Medical Center), Albert Oriol(Institut Català d'Oncologia), Andreas Kirsch, Rajesh Bandekar(Springhouse), Matthew Streetly(King's College - North Carolina), David Ghez(Hôpital Necker-Enfants Malades), Ming Qi(Janssen (United States)), Peter Hu(Janssen (United States)), Simon J. Harrison(Peter MacCallum Cancer Centre), Brendan M. Weiss(Heidelberg University), Xiang Qin(Changsha Medical University), Mercedes Gironella(Vall d'Hebron Hospital Universitari)
Cited by 6
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719